| Identification | Back Directory | [Name]
3-cyclohexyl-5-fluoro-6-methyl-7-[2-(morpholin-4-yl)ethoxy]-4H-chromen-4-one | [CAS]
1190598-60-7 | [Synonyms]
CFMMC
3-cyclohexyl-5-fluoro-6-methyl-7-[2-(morpholin-4-yl)ethoxy]-4H-chromen-4-one | [Molecular Formula]
C22H28FNO4 | [MDL Number]
MFCD28160460 | [MOL File]
1190598-60-7.mol | [Molecular Weight]
389.47 |
| Hazard Information | Back Directory | [Description]
CFMMC is an allosteric mGluR1 antagonist. | [Uses]
CFMMC is a selective allosteric metabotropic glutamate receptor 1 (mGluR1) antagonist. CFMMC inhibits L-glutamate-induced intracellular Ca2+ mobilization ([Ca2+]i) in Chinese hamster ovary cells expressing recombinant human mGluR1a with an IC50 value of 50 nM. CFMMC is promising for research of various central nervous system disorders, such as schizophrenia, epilepsy, anxiety, pain, cognitive dysfunction and drug abuse[1]. | [References]
[1] Fukuda J, et al. Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology. 2009 Sep;57(4):438-45. DOI:10.1016/j.neuropharm.2009.06.017 |
|
|